Next Article in Journal
Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen
Next Article in Special Issue
Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
Previous Article in Journal
The CCL5/CCR5 Axis in Cancer Progression
Previous Article in Special Issue
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
 
 
Review

Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer

1
Cancer Research Center of Toulouse (CRCT), Institut National de la Santé Et de la Recherche Médicale (INSERM) Unité 1037, 31037 Toulouse, France
2
Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT), 31037 Toulouse, France
3
Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, 31037 Toulouse, France
4
Université Toulouse III Paul Sabatier, 31037 Toulouse, France
5
Immune Monitoring Core Facility, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, 31037 Toulouse, France
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1761; https://doi.org/10.3390/cancers12071761
Received: 7 June 2020 / Revised: 24 June 2020 / Accepted: 26 June 2020 / Published: 2 July 2020
(This article belongs to the Special Issue Preclinical and Clinical Advances in Ovarian Cancer)
In the past 20 years, the immune system has increasingly been recognized as a major player in tumor cell control, leading to considerable advances in cancer treatment. While promising with regards to melanoma, renal cancer and non-small cell lung cancer, immunotherapy provides, for the time being, limited success in other cancers, including ovarian cancer, potentially due to insufficient immunogenicity or to a particularly immunosuppressive microenvironment. In this review, we provide a global description of the immune context of ovarian cancer, in particular epithelial ovarian cancer (EOC). We describe the adaptive and innate components involved in the EOC immune response, including infiltrating tumor-specific T lymphocytes, B lymphocytes, and natural killer and myeloid cells. In addition, we highlight the rationale behind the use of EOC preclinical mouse models to assess resistance to immunotherapy, and we summarize the main preclinical studies that yielded anti-EOC immunotherapeutic strategies. Finally, we focus on major published or ongoing immunotherapy clinical trials concerning EOC. View Full-Text
Keywords: epithelial ovarian cancer; immune contexture; tumor microenvironment; adaptive and innate immune responses; lymphocytes; immunogenicity; myeloid cells; immunotherapy; preclinical mouse models; clinical trials epithelial ovarian cancer; immune contexture; tumor microenvironment; adaptive and innate immune responses; lymphocytes; immunogenicity; myeloid cells; immunotherapy; preclinical mouse models; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Martinez, A.; Delord, J.-P.; Ayyoub, M.; Devaud, C. Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers 2020, 12, 1761. https://doi.org/10.3390/cancers12071761

AMA Style

Martinez A, Delord J-P, Ayyoub M, Devaud C. Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers. 2020; 12(7):1761. https://doi.org/10.3390/cancers12071761

Chicago/Turabian Style

Martinez, Alejandra, Jean-Pierre Delord, Maha Ayyoub, and Christel Devaud. 2020. "Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer" Cancers 12, no. 7: 1761. https://doi.org/10.3390/cancers12071761

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop